MIRM
NASDAQMirum Pharmaceuticals Inc.
Price$107.76-1.48 (-1.35%)
01:30 PM07:45 PM
News · 26 weeks117+50%
2025-12-282026-06-21
Mix5090d
- Insider18(36%)
- SEC Filings14(28%)
- Other12(24%)
- Earnings4(8%)
- Analyst2(4%)
Latest news
25 items- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda sold $264,458 worth of shares (2,594 units at $101.95) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 5,835 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 8-K filed by Mirum Pharmaceuticals Inc.8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- INSIDERSEC Form 4 filed by Director Walbert Timothy P4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Cardon Lon4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Ramasastry Saira4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairey William4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Brege Laura4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Fischer Laurent4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Heron Patrick J4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSEC Form 4 filed by Director Grey Michael G4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- PRMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,100 shares of common stock and 13,350 restricted stock units ("RSUs") to 8 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).Each stock option has an exercise price of $94.00 per share, which is equal to the closing price of Mirum's common stock on June 10, 20
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric sold $469,077 worth of shares (5,000 units at $93.82) as part of a pre-agreed trading plan and exercised 2,393 shares at a strike of $26.49, decreasing direct ownership by 5% to 47,181 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERPRESIDENT AND COO Radovich Peter exercised 16,988 shares at a strike of $19.19, increasing direct ownership by 42% to 57,260 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva ("FOP") will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604863826/en/
- INSIDERDirector Cardon Lon converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,875,103 worth of shares (30,000 units at $95.84) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Walbert Timothy P converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Fischer Laurent converted options into 3,977 shares, increasing direct ownership by 59% to 10,727 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Ramasastry Saira converted options into 3,977 shares and sold $397,700 worth of shares (3,977 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- ANALYSTCitigroup initiated coverage on Mirum Pharmaceuticals with a new price targetCitigroup initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $145.00
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease - Treatment with LIVMARLI® (maralixibat) demonstrates improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS s
MIRM FAQ
7 questionsWhat does Mirum Pharmaceuticals Inc. do?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was...Where does MIRM stock trade?
Mirum Pharmaceuticals Inc. (MIRM) is listed on NASDAQ.What sector and industry is MIRM in?
Mirum Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mirum Pharmaceuticals Inc. go public?
Mirum Pharmaceuticals Inc. (MIRM) completed its IPO in 2019.What are analysts saying about MIRM?
Mirum Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-02. Recent price targets cluster around $4800.00.What companies are similar to MIRM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MIRM side-by-side with any of them on Quantisnow.How can I track MIRM on Quantisnow?
Quantisnow aggregates Mirum Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRM to receive live email and push alerts on every new disclosure.